The US Food and Drug Administration iw widening the enquiry, seeking more data from clinical trials
- FDA seeking raw safety data from clinical trials of similar vaccines developed by same scientists
- The FDA does not necessarily indicate a safety problem associated with any of those vaccines
The market has been acting constructively on positive coronavirus vaccine stories. This is not a positive (in the short term at least) so should impact the opposite on risk.
Reuters have a report with further detail here:
- AstraZeneca’s large, late-stage U.S. trial has remained on hold since Sept. 6, after a study participant in Britain fell ill
- The widened scope of the FDA probe raises the likelihood of additional delays for what has been one of the most advanced COVID-19 vaccine candidates in development. The requested data was expected to arrive this week, after which the FDA would need time to analyze it, two of the sources said.